Economic Burden of Immune Thrombocytopenia (ITP) In Patients Receiving Eltrombopag (EPAG) And Romiplostim (ROMI)- Real World Evidence From 26 US Institutions
Abstract
Authors
A Forsythe M Bhor A Roy M Socorro O Portella C Kwon G Tremblay